Tradestie Institutional Equity Comparison Engine

RIGL vs BCRX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RIGL Overall Edge

RIGL Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Rigel Pharmaceuticals Inc. (New) (RIGL) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while BCRX counters with relative strength in Valuation. Fundamentally, RIGL trades at 9.3x Forward P/E with 26.3% operating margin (+16.5% YoY revenue) versus BCRX at 8.9x Forward P/E and 48.8% operating margin (+13.1% YoY). In options structure, RIGL sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro) against BCRX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BCRX
RIGL 9.3x vs BCRX 8.9x Fwd P/E
Growth & Margin Winner RIGL
Op Margin 26.3% vs 48.8% ยท YoY +16.5% vs +13.1%
Momentum & Technical Winner RIGL
1Y +9.7% vs +9.1% ยท 52W Pos 68% vs 26%
Options & Structure Winner RIGL
CONSOLIDATION (4th %ile IV) vs BREAKDOWN (12th %ile IV)
RIGL NASDAQ
Rigel Pharmaceuticals Inc. (New)
Pharmaceutical Preparations
$43.73
-1.64% 1D
Market Cap $860.3M
1M Return -4.87%
1Y Return +9.65%
Forward P/E 9.3x
Unified AI Score
59.9 / 100 HOLD
Tech 48.0 Fund 58.0 Flow 68.0 Mom 60.0
BCRX NASDAQ
BioCryst Pharmaceuticals Inc
Biological Products, (No Disgnostic Substances)
$7.53
-1.05% 1D
Market Cap $1.9B
1M Return -3.34%
1Y Return +9.13%
Forward P/E 8.9x
Unified AI Score
42.2 / 100 HOLD
Tech 24.0 Fund 52.0 Flow 67.0 Mom 68.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RIGL +9.65% BCRX +9.13% Spread: +0.52 pp (RIGL Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RIGL Revenue BCRX Revenue RIGL Op. Margin BCRX Op. Margin Margin Edge
FY2018 $40M $20M -163.3% -456.2% RIGL
FY2019 $60M $50M -116.5% -203.7% RIGL
FY2020 $110M $20M -26.7% -981.1% RIGL
FY2021 $150M $160M -8.4% -113.1% RIGL
FY2022 $120M $270M -46.2% -54.8% RIGL
FY2023 $120M $330M -17.5% -31.3% RIGL
FY2024 $180M $450M 13.5% -0.6% RIGL
FY2025 $290M $870M 42.6% 39.0% RIGL

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RIGL (6) vs BCRX (4)
Institutional Metric RIGL BCRX Criterion Row Winner
Market Capitalization Scale $860.3M $1.9B Larger Scale BCRX
Trailing P/E Ratio Valuation 2.8x 13.0x Lower Multiple RIGL
Forward P/E Ratio Valuation 9.3x 8.9x Lower Multiple BCRX
Revenue Growth (YoY) Growth +16.5% +13.1% Higher Growth RIGL
Operating Margin (TTM) Profitability 26.3% 48.8% Higher Margin BCRX
Net Profit Margin Profitability 106.6% -37.4% Higher Margin RIGL
Return on Equity (ROE) Capital Efficiency 109.2% -1925.4% Higher ROE RIGL
52-Week Range Position Momentum 68% ($25โ€“$53) 26% ($6โ€“$11) Stronger Trend RIGL
Beta / 30D Volatility Risk Regime 1.05ฮฒ ยท 74% Vol 0.77ฮฒ ยท 42% Vol Lower Realized Risk BCRX
Unified Institutional Score Composite Signal 59.9 / 100 (HOLD) 42.2 / 100 (HOLD) Higher Composite RIGL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RIGL vs BCRX Buy Guide
RIGL CONSOLIDATION
91d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live RIGL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BCRX BREAKDOWN
92d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live BCRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RIGL nor BCRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.